Taiwan · Delayed Price · Currency is TWD Adimmune Company Description
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally.
The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury.
It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine.
The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001.
Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
| Country | Taiwan |
| Founded | 1965 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 564 |
| CEO | Chi-Hsien Chan |
Contact Details
Address: No. 3, Tanxing Road Taichung, 427003 Taiwan | |
| Phone | 886 4 2538 1220 |
| Website | adimmune.com.tw |
Stock Details
| Ticker Symbol | 4142 |
| Exchange | Taiwan Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004142005 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chi-Hsien Chan | Chief Executive Officer and Chairman |
| Chin-Chuan Chang | Chief Operating Officer and Vice President of Research & Development |
| Chin-I Chiu | Vice President of Quality Assurance Department |
| Yin-Teng Chang | Chief Financial Officer and Accounting Supervisor |
| Li-Ya Tang | Director of Administration Center |
| Fei Pan | Chief Legal Officer and General Counsel |
| Zhe Wei Zhang | Executive Vice GM |
| Chih-Hsiang Leng | Head of Research & Development Division |
| Cheng Liu Churg | Acting Research & Development Officer |